Cancer drug design and discovery:
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam [u.a.]
Elsevier [u.a.]
2008
|
| Ausgabe: | 1. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XV, 473 S., [13] Bl. Ill., graph. Darst. |
| ISBN: | 9780123694485 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV023013944 | ||
| 003 | DE-604 | ||
| 005 | 20080807 | ||
| 007 | t| | ||
| 008 | 071121s2008 xx ad|| |||| 00||| eng d | ||
| 020 | |a 9780123694485 |9 978-0-12-369448-5 | ||
| 035 | |a (OCoLC)262262325 | ||
| 035 | |a (DE-599)HBZHT015260218 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-703 |a DE-19 | ||
| 050 | 0 | |a RS431.A64 | |
| 082 | 0 | |a 616.994061 |2 22 | |
| 084 | |a VS 9100 |0 (DE-625)147725:253 |2 rvk | ||
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Cancer drug design and discovery |c ed. by Stephen Neidle |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Amsterdam [u.a.] |b Elsevier [u.a.] |c 2008 | |
| 300 | |a XV, 473 S., [13] Bl. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Antineoplastic Agents | |
| 650 | 4 | |a Antineoplastic agents |x Design | |
| 650 | 4 | |a Antineoplastic agents |x Development | |
| 650 | 4 | |a Cancer |x Chemotherapy | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebsforschung |0 (DE-588)4165564-3 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebsforschung |0 (DE-588)4165564-3 |D s |
| 689 | 0 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Neidle, Stephen |4 edt | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016218133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-016218133 | |
Datensatz im Suchindex
| _version_ | 1823607502112030720 |
|---|---|
| adam_text |
Contents
About the editor x
Contributors xi
Introduction xiv
PART I: BASIC PRINCIPLES 1
1 Modern cancer drug discovery: integrating targets, technologies and treatments 3
Paul Workman and Ian Collins
1.1 Introduction: changing times 3
1.2 Successes and limitations 4
1.3 Integrated small-molecule drug discovery and development 10
1.4 New molecular targets: the "druggable" cancer genome 10
1.5 From drug target to development candidate 16
1.6 Examples of case histories for molecularly targeted cancer therapeutics 24
1.7 Biomarkers, the pharmacological audit trail and clinical development 26
1.8 Conclusions and outlook: towards individualized molecular cancer medicine 29
References 33
2 Preclinical pharmacology and in vivo models 39
Lloyd Kelhnd
2.1 Introduction 39
2.2 Contemporary preclinical cancer drug discovery 40
2.3 In vitro pharmacological evaluation 41
2.4 Information gained from in vitro cell lines 42
2.5 In two pharmacokinetics (PK) and pharmacodynamics (PD): continuing the
pharmacological audit trail 43
2.6 In vivo anti-tumor models: choice and predictiveness? 45
2.7 Concluding remarks 50
References 51
3 Clinical trial designs for more rapid proof-of-principle and approval 53
Mitesh ]. Borad and Daniel D. Von Hoff
3.1 Introduction 53
3.2 NDA plan at the time of IND 54
3.3 Phase I trial design innovations 54
3.4 Concept of a continuous Phase I 59
vi CONTENTS
3.5 Phase II trial design innovations 60
3.6 Phase III trial design innovations (enrichment designs) 67
3.7 Other approaches to enrich trial populations 72
3.8 Innovations in design and selection of endpoints 73
3.9 Regulatory strategies 77
3.10 Other approaches to accelerate drug development 78
3.11 New perspectives 79
3.12 Summary 81
References 83
PART II: METHODOLOGY 89
4 Structural biology and anticancer drug design 91
Dominic Tisi, Gianni Chessari, Andrew]. Woodhead and Harren]hoti
4-1 Introduction 91
4-2 High-throughput X-ray crystallography 93
4-3 Structural biology and structure-based drug design 95
4-4 Fragment screening using X-ray crystallography 97
4-5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical
candidate 98
4-6 Compound profiling 102
4-7 Conclusions 104
References 105
5 Natural product chemistry and anticancer drug discovery 107
Donna M. Huryn and Peter Wipf
5.1 Introduction 107
5.2 Exemestane (aromasin) 108
5.3 Fulvestrant/faslodex 109
5.4 Flavonoids 110
5.5 Bexarotene (targretin) 111
5.6 Epothilones 112
5.7 Maytansine 114
5.8 Geldanamycin 115
5.9 UCN-01 116
5.10 Camptothecin 117
5.11 Prodigiosin 118
5.12 Azacitidine 119
5.13 FK-288 121
5.14 Hemiasterlin 122
5.15 Calicheamicin 124
5.16 Conclusion 126
References 126
6 Pharmacokinetics and ADME optimization in drug discovery 131
Chad L. Stoner, Matthew D. Troutman and Caroline E. Laverty
6.1 Introduction 131
6.2 Absorption 133
CONTENTS Vii
6.3 Distribution 140
6.4 Metabolism 142
6.5 Elimination 145
6.6 Biochemical barriers to drug therapy: efflux transporters 145
6.7 Induction 147
6.8 Conclusions 148
References 149
PART III: DRUGS IN THE CLINIC 155
7 Temozolomide: from cytotoxic to molecularly-targeted agent 157
Malcolm F. G. Stevens
7.1 Introduction 157
7.2 Towards imidazotetrazines and azolastone (mitozolomide) 158
7.3 From mitozolomide to temozolomide 160
7.4 Synthesis and chemistry of temozolomide 161
7.5 Early clinical trials on temozolomide 163
7.6 Mode of action of temozolomide 163
7.7 Epigenetic silencing of the MGMT gene 167
7.8 New analogs of temozolomide 167
7.9 Summary: temozolomide, targets, molecular targets and validated targets 168
References 169
8 Camptothecins for drug design, cancer cell death and gene targeting 173
Jerome Kluza, Paola B. Arimondo, Marie-Helene David-Cordonnier
and Christian Bailly
8.1 Introduction 173
8.2 Camptothecins: molecular clamps for the topoisomerase I-DNA complex 174
8.3 Design of CPT derivatives: an endless series 177
8.4 From trapped-topoisomerase I to DNA double strand breaks 182
8.5 DNA repair or cell death 183
8.6 Sequence-specific targeting of topoisomerase-mediated DNA cleavage 186
8.7 Structure-activity relationships 188
8.8 Applications 189
8.9 Conclusion 190
References 190
9 Targeting thymidylate synthase by antifolate drugs for the treatment of cancer 198
Ann L. Jackman, Martin Forster and Matthew Ng
9.1 Introduction 198
9.2 Thymidylate synthase as an anti-cancer drug target 199
9.3 CB3717 200
9.4 Raltitrexed 202
9.5 Pemetrexed 207
9.6 Plevitrexed 210
9.7 BGC945 214
9.8 Conclusions 218
References 219
Viii CONTENTS
PART IV: NEW AGENTS 227
10 Targeting inactive kinases: structure as a foundation for cancer drug discovery 229
David]. Hosfield and Clifford D. Mol
10.1 Introduction 229
10.2 c-Kit, a Type III receptor protein tyrosine kinase 230
10.3 c-Abl, a cellular protein tyrosine kinase 239
10.4 b-Raf-Bay43-9006 co-crystal structure 244
10.5 P38-BIRB-796 co-crystal structure 245
10.6 VEGF-R2^-amino-furopyrimidine co-crystal structure 246
10.7 Conclusions and perspectives 249
References 250
11 Cell cycle inhibitors in cancer: current status and future directions 253
Peter M. Fischer
11.1 Introduction 253
11.2 The Gl-S nexus 255
11.3 The DN A replication and damage checkpoints 260
11.4 Mitosis 266
11.5 Conclusion 278
References 279
12 Inhibition of DN A repair as a therapeutic target 284
Nicola ]. Curtin and Thomas Helkday
12.1 Introduction 284
12.2 O6-Alkylguanine DNA alkyltransferase (AGT) 286
12.3 Poly(ADP-ribose) polymerase (PARP) 289
12.4 DNA-dependent protein kinase (DNA-PK) 295
12.5 Exploiting synthetic lethality for cancer treatments 297
12.6 Summary and conclusions 300
References 300
13 HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade
of oncogenic pathways 305
Swee YSharp, Keith]ones and Paul Workman
13.1 Introduction 305
13.2 Classes of HSP90 inhibitors 310
13.3 Summary and future perspectives 326
References 329
14 Heat shock protein-90 directed therapeutics and target validation 336
Edward A. Sausville
14-1 Introduction 336
14-2 Overview of heat shock protein function 337
14-3 Benzoquinoid ansamycin HSP90 antagonists 339
14-4 Radicicol (monorden) 343
CONTENTS ix
14-5 Radester, radamide, and radanamycin 344
14-6 Purine scaffold inhibitors: PU3 and analogs 344
14-7 Pyrazole resorcinols 344
14-8 Shepherdin-related structures 345
14.9 Novobiocin and analogs 346
14-10 Conclusion and perspectives 347
References 347
15 Inhibitors of tumor angiogenesis 351
Adrian L Harris and Daniele G. Generali
15.1 Introduction: overview of tumor angiogenesis 351
15.2 Tumor angiogenesis: assessment approaches 353
15.3 Tumor angiogenesis-related pathways and anti-angiogenic drugs 356
15.4 Conclusions and future directions 373
References 374
16 The biology and oncology of RAF-ERK signaling 382
Victoria Emuss and Richard Kiarais
16.1 Introduction 382
16.2 MAP kinase pathways 383
16.3 Outcomes of ERK signaling 384
16.4 RAF proteins 385
16.5 ERK signaling and cancer 390
16.6 Therapeutic opportunities 392
16.7 Conclusions 396
References 397
PART V: THE REALITY OF CANCER DRUGS IN THE CLINIC 403
17 Cancer drug resistance 405
V. Karavasilis, A. Reid, R. Sinha andJ.S. de Bono
17.1 Introduction 405
17.2 Drug resistance in conventional chemotherapy 406
17.3 Targeted therapeutics 410
17.4 Conclusions: overcoming resistance to TKI inhibitors 420
References 422
18 Failure modes in anticancer drug discovery and development 424
Homer L. Pearce, Kerry L. Blanchard and Christopher A. Slapak
18.1 Introduction 424
18.2 Failure modes in the discovery process 425
18.3 Failure modes in clinical development 430
18.4 Conclusions 433
References 434
Glossary 436
Index 440 |
| adam_txt |
Contents
About the editor x
Contributors xi
Introduction xiv
PART I: BASIC PRINCIPLES 1
1 Modern cancer drug discovery: integrating targets, technologies and treatments 3
Paul Workman and Ian Collins
1.1 Introduction: changing times 3
1.2 Successes and limitations 4
1.3 Integrated small-molecule drug discovery and development 10
1.4 New molecular targets: the "druggable" cancer genome 10
1.5 From drug target to development candidate 16
1.6 Examples of case histories for molecularly targeted cancer therapeutics 24
1.7 Biomarkers, the pharmacological audit trail and clinical development 26
1.8 Conclusions and outlook: towards individualized molecular cancer medicine 29
References 33
2 Preclinical pharmacology and in vivo models 39
Lloyd Kelhnd
2.1 Introduction 39
2.2 Contemporary preclinical cancer drug discovery 40
2.3 In vitro pharmacological evaluation 41
2.4 Information gained from in vitro cell lines 42
2.5 In two pharmacokinetics (PK) and pharmacodynamics (PD): continuing the
pharmacological audit trail 43
2.6 In vivo anti-tumor models: choice and predictiveness? 45
2.7 Concluding remarks 50
References 51
3 Clinical trial designs for more rapid proof-of-principle and approval 53
Mitesh ]. Borad and Daniel D. Von Hoff
3.1 Introduction 53
3.2 NDA plan at the time of IND 54
3.3 Phase I trial design innovations 54
3.4 Concept of a continuous Phase I 59
vi CONTENTS
3.5 Phase II trial design innovations 60
3.6 Phase III trial design innovations (enrichment designs) 67
3.7 Other approaches to enrich trial populations 72
3.8 Innovations in design and selection of endpoints 73
3.9 Regulatory strategies 77
3.10 Other approaches to accelerate drug development 78
3.11 New perspectives 79
3.12 Summary 81
References 83
PART II: METHODOLOGY 89
4 Structural biology and anticancer drug design 91
Dominic Tisi, Gianni Chessari, Andrew]. Woodhead and Harren]hoti
4-1 Introduction 91
4-2 High-throughput X-ray crystallography 93
4-3 Structural biology and structure-based drug design 95
4-4 Fragment screening using X-ray crystallography 97
4-5 Case history: cyclin-dependent kinase inhibitors, from fragment hit to clinical
candidate 98
4-6 Compound profiling 102
4-7 Conclusions 104
References 105
5 Natural product chemistry and anticancer drug discovery 107
Donna M. Huryn and Peter Wipf
5.1 Introduction 107
5.2 Exemestane (aromasin) 108
5.3 Fulvestrant/faslodex 109
5.4 Flavonoids 110
5.5 Bexarotene (targretin) 111
5.6 Epothilones 112
5.7 Maytansine 114
5.8 Geldanamycin 115
5.9 UCN-01 116
5.10 Camptothecin 117
5.11 Prodigiosin 118
5.12 Azacitidine 119
5.13 FK-288 121
5.14 Hemiasterlin 122
5.15 Calicheamicin 124
5.16 Conclusion 126
References 126
6 Pharmacokinetics and ADME optimization in drug discovery 131
Chad L. Stoner, Matthew D. Troutman and Caroline E. Laverty
6.1 Introduction 131
6.2 Absorption 133
CONTENTS Vii
6.3 Distribution 140
6.4 Metabolism 142
6.5 Elimination 145
6.6 Biochemical barriers to drug therapy: efflux transporters 145
6.7 Induction 147
6.8 Conclusions 148
References 149
PART III: DRUGS IN THE CLINIC 155
7 Temozolomide: from cytotoxic to molecularly-targeted agent 157
Malcolm F. G. Stevens
7.1 Introduction 157
7.2 Towards imidazotetrazines and azolastone (mitozolomide) 158
7.3 From mitozolomide to temozolomide 160
7.4 Synthesis and chemistry of temozolomide 161
7.5 Early clinical trials on temozolomide 163
7.6 Mode of action of temozolomide 163
7.7 Epigenetic silencing of the MGMT gene 167
7.8 New analogs of temozolomide 167
7.9 Summary: temozolomide, targets, molecular targets and validated targets 168
References 169
8 Camptothecins for drug design, cancer cell death and gene targeting 173
Jerome Kluza, Paola B. Arimondo, Marie-Helene David-Cordonnier
and Christian Bailly
8.1 Introduction 173
8.2 Camptothecins: molecular clamps for the topoisomerase I-DNA complex 174
8.3 Design of CPT derivatives: an endless series 177
8.4 From trapped-topoisomerase I to DNA double strand breaks 182
8.5 DNA repair or cell death 183
8.6 Sequence-specific targeting of topoisomerase-mediated DNA cleavage 186
8.7 Structure-activity relationships 188
8.8 Applications 189
8.9 Conclusion 190
References 190
9 Targeting thymidylate synthase by antifolate drugs for the treatment of cancer 198
Ann L. Jackman, Martin Forster and Matthew Ng
9.1 Introduction 198
9.2 Thymidylate synthase as an anti-cancer drug target 199
9.3 CB3717 200
9.4 Raltitrexed 202
9.5 Pemetrexed 207
9.6 Plevitrexed 210
9.7 BGC945 214
9.8 Conclusions 218
References 219
Viii CONTENTS
PART IV: NEW AGENTS 227
10 Targeting inactive kinases: structure as a foundation for cancer drug discovery 229
David]. Hosfield and Clifford D. Mol
10.1 Introduction 229
10.2 c-Kit, a Type III receptor protein tyrosine kinase 230
10.3 c-Abl, a cellular protein tyrosine kinase 239
10.4 b-Raf-Bay43-9006 co-crystal structure 244
10.5 P38-BIRB-796 co-crystal structure 245
10.6 VEGF-R2^-amino-furopyrimidine co-crystal structure 246
10.7 Conclusions and perspectives 249
References 250
11 Cell cycle inhibitors in cancer: current status and future directions 253
Peter M. Fischer
11.1 Introduction 253
11.2 The Gl-S nexus 255
11.3 The DN A replication and damage checkpoints 260
11.4 Mitosis 266
11.5 Conclusion 278
References 279
12 Inhibition of DN A repair as a therapeutic target 284
Nicola ]. Curtin and Thomas Helkday
12.1 Introduction 284
12.2 O6-Alkylguanine DNA alkyltransferase (AGT) 286
12.3 Poly(ADP-ribose) polymerase (PARP) 289
12.4 DNA-dependent protein kinase (DNA-PK) 295
12.5 Exploiting synthetic lethality for cancer treatments 297
12.6 Summary and conclusions 300
References 300
13 HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade
of oncogenic pathways 305
Swee YSharp, Keith]ones and Paul Workman
13.1 Introduction 305
13.2 Classes of HSP90 inhibitors 310
13.3 Summary and future perspectives 326
References 329
14 Heat shock protein-90 directed therapeutics and target validation 336
Edward A. Sausville
14-1 Introduction 336
14-2 Overview of heat shock protein function 337
14-3 Benzoquinoid ansamycin HSP90 antagonists 339
14-4 Radicicol (monorden) 343
CONTENTS ix
14-5 Radester, radamide, and radanamycin 344
14-6 Purine scaffold inhibitors: PU3 and analogs 344
14-7 Pyrazole resorcinols 344
14-8 Shepherdin-related structures 345
14.9 Novobiocin and analogs 346
14-10 Conclusion and perspectives 347
References 347
15 Inhibitors of tumor angiogenesis 351
Adrian L Harris and Daniele G. Generali
15.1 Introduction: overview of tumor angiogenesis 351
15.2 Tumor angiogenesis: assessment approaches 353
15.3 Tumor angiogenesis-related pathways and anti-angiogenic drugs 356
15.4 Conclusions and future directions 373
References 374
16 The biology and oncology of RAF-ERK signaling 382
Victoria Emuss and Richard Kiarais
16.1 Introduction 382
16.2 MAP kinase pathways 383
16.3 Outcomes of ERK signaling 384
16.4 RAF proteins 385
16.5 ERK signaling and cancer 390
16.6 Therapeutic opportunities 392
16.7 Conclusions 396
References 397
PART V: THE REALITY OF CANCER DRUGS IN THE CLINIC 403
17 Cancer drug resistance 405
V. Karavasilis, A. Reid, R. Sinha andJ.S. de Bono
17.1 Introduction 405
17.2 Drug resistance in conventional chemotherapy 406
17.3 Targeted therapeutics 410
17.4 Conclusions: overcoming resistance to TKI inhibitors 420
References 422
18 Failure modes in anticancer drug discovery and development 424
Homer L. Pearce, Kerry L. Blanchard and Christopher A. Slapak
18.1 Introduction 424
18.2 Failure modes in the discovery process 425
18.3 Failure modes in clinical development 430
18.4 Conclusions 433
References 434
Glossary 436
Index 440 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Neidle, Stephen |
| author2_role | edt |
| author2_variant | s n sn |
| author_facet | Neidle, Stephen |
| building | Verbundindex |
| bvnumber | BV023013944 |
| callnumber-first | R - Medicine |
| callnumber-label | RS431 |
| callnumber-raw | RS431.A64 |
| callnumber-search | RS431.A64 |
| callnumber-sort | RS 3431 A64 |
| callnumber-subject | RS - Pharmacy |
| classification_rvk | VS 9100 XH 3200 |
| ctrlnum | (OCoLC)262262325 (DE-599)HBZHT015260218 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| discipline_str_mv | Chemie / Pharmazie Medizin |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV023013944</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080807</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">071121s2008 xx ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123694485</subfield><subfield code="9">978-0-12-369448-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)262262325</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HBZHT015260218</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-703</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS431.A64</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9100</subfield><subfield code="0">(DE-625)147725:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer drug design and discovery</subfield><subfield code="c">ed. by Stephen Neidle</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam [u.a.]</subfield><subfield code="b">Elsevier [u.a.]</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 473 S., [13] Bl.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield><subfield code="x">Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield><subfield code="x">Development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebsforschung</subfield><subfield code="0">(DE-588)4165564-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebsforschung</subfield><subfield code="0">(DE-588)4165564-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neidle, Stephen</subfield><subfield code="4">edt</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016218133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016218133</subfield></datafield></record></collection> |
| id | DE-604.BV023013944 |
| illustrated | Illustrated |
| index_date | 2024-07-02T19:10:30Z |
| indexdate | 2025-02-09T19:00:37Z |
| institution | BVB |
| isbn | 9780123694485 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016218133 |
| oclc_num | 262262325 |
| open_access_boolean | |
| owner | DE-703 DE-19 DE-BY-UBM |
| owner_facet | DE-703 DE-19 DE-BY-UBM |
| physical | XV, 473 S., [13] Bl. Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Elsevier [u.a.] |
| record_format | marc |
| spelling | Cancer drug design and discovery ed. by Stephen Neidle 1. ed. Amsterdam [u.a.] Elsevier [u.a.] 2008 XV, 473 S., [13] Bl. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Antineoplastic Agents Antineoplastic agents Design Antineoplastic agents Development Cancer Chemotherapy Drug Design Neoplasms drug therapy Cytostatikum (DE-588)4068347-3 gnd rswk-swf Krebsforschung (DE-588)4165564-3 gnd rswk-swf Krebsforschung (DE-588)4165564-3 s Cytostatikum (DE-588)4068347-3 s DE-604 Neidle, Stephen edt HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016218133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Cancer drug design and discovery Antineoplastic Agents Antineoplastic agents Design Antineoplastic agents Development Cancer Chemotherapy Drug Design Neoplasms drug therapy Cytostatikum (DE-588)4068347-3 gnd Krebsforschung (DE-588)4165564-3 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4165564-3 |
| title | Cancer drug design and discovery |
| title_auth | Cancer drug design and discovery |
| title_exact_search | Cancer drug design and discovery |
| title_exact_search_txtP | Cancer drug design and discovery |
| title_full | Cancer drug design and discovery ed. by Stephen Neidle |
| title_fullStr | Cancer drug design and discovery ed. by Stephen Neidle |
| title_full_unstemmed | Cancer drug design and discovery ed. by Stephen Neidle |
| title_short | Cancer drug design and discovery |
| title_sort | cancer drug design and discovery |
| topic | Antineoplastic Agents Antineoplastic agents Design Antineoplastic agents Development Cancer Chemotherapy Drug Design Neoplasms drug therapy Cytostatikum (DE-588)4068347-3 gnd Krebsforschung (DE-588)4165564-3 gnd |
| topic_facet | Antineoplastic Agents Antineoplastic agents Design Antineoplastic agents Development Cancer Chemotherapy Drug Design Neoplasms drug therapy Cytostatikum Krebsforschung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016218133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT neidlestephen cancerdrugdesignanddiscovery |